, Volume 73, Issue 1, pp 31–43 | Cite as

Glucocorticoids in Rheumatoid Arthritis

  • Roberto Caporali
  • Monica Todoerti
  • Garifallia Sakellariou
  • Carlomaurizio Montecucco
Review Article


Interest in the numerous benefits of corticosteroid medication in the management of rheumatoid arthritis (RA) goes back to the mid-1950s, and has recently been renewed. The established evidence of their rapid symptomatic effects, along with the growing recognition of their long-lasting disease-modifying properties and preliminary data about their sub-clinical action, led us to reconsider the potential of corticosteroids in the treatment of RA, given their acceptable safety profile, especially when used at low dosages. Over time, several corticosteroid-based therapeutic approaches have been explored in order to optimize their clinical benefits, while limiting the adverse effects. Clinical data reported with initial high-dosage corticosteroid schedules with subsequent step-down schemes suggest clinical efficacy, but are not applicable to patient management in a real-life setting. Encouraging results on the clinical and sub-clinical effects of low dosages have led to a shift in usual daily practice. We present past and recent efforts to clarify the role of corticosteroids in the treatment of RA, focusing on the best approach in terms of dose and timing of corticosteroid administration. Additional information about different routes of administration, step-down schedules and adverse effects are also considered.



Native English editing, formatting and styling of the draft manuscript was provided by Mary Hines, inScience Communications, Springer Healthcare and funded by Mundipharma Pharmaceuticals srl.

Conflicts of interest


Authors’ contributions

Professor Caporali took the main responsibility for the planning of the work and for the accuracy and integrity of the data reported. Professor Montecucco revised and approved the final manuscript. Dr Sakellariou and Dr Todoerti were responsible for the data search, acquisition and reporting.


  1. 1.
    Caporali R, Cimmino MA, Montecucco C, et al. Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S143–7.Google Scholar
  2. 2.
    Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1010–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–7.PubMedCrossRefGoogle Scholar
  4. 4.
    OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. 2012. http://www.cebm.net/index.aspx?o=5653. Accessed 2012.
  5. 5.
    The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis; a report by the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases. Br Med J. 1954;1(4873):1223–7.Google Scholar
  6. 6.
    The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of prednisolone with aspirin on other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1959;18:173–88.Google Scholar
  7. 7.
    The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. A second report by the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases. Ann Rheum Dis. 1960;19:331–7.Google Scholar
  8. 8.
    Empire Rheumatism Council. Multicentre controlled trial comparing cortisone acetate and acetylsalicylic acid in the long-term treatment of rheumatoid arthritis. Ann Rheum Dis. 1955;14(4):353–70.CrossRefGoogle Scholar
  9. 9.
    Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(2):CD001158.Google Scholar
  10. 10.
    Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(3):CD000189.Google Scholar
  11. 11.
    Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347–56.PubMedCrossRefGoogle Scholar
  12. 12.
    Boers M, Verhoeven AC, van der Linden S. Combination therapy in early rheumatoid arthritis: the COBRA study [in Dutch]. Ned Tijdschr Geneeskd. 1997;141(50):2428–32.PubMedGoogle Scholar
  13. 13.
    van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69(5):807–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70(2):315–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004;63(7):797–803.PubMedCrossRefGoogle Scholar
  17. 17.
    Hansen M, Podenphant J, Florescu A, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58(11):713–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52(11):3360–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Todoerti M, Scire CA, Boffini N, et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci. 2010;1193:139–45.PubMedCrossRefGoogle Scholar
  20. 20.
    Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Pincus T, Castrejon I, Sokka T. Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S130–8.Google Scholar
  22. 22.
    Harris ED Jr, Emkey RD, Nichols JE, et al. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol. 1983;10(5):713–21.PubMedGoogle Scholar
  23. 23.
    Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333(3):142–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998;37(9):930–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Hafstrom I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis. 2009;68(4):508–13.PubMedCrossRefGoogle Scholar
  26. 26.
    van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Jacobs JW, van Everdingen AA, Verstappen SM, et al. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 2006;54(5):1422–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329–39.PubMedCrossRefGoogle Scholar
  29. 29.
    Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54(12):3761–73.PubMedCrossRefGoogle Scholar
  30. 30.
    Bugatti S, Manzo A, Benaglio F, et al. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther. 2012;14(1):R34.PubMedCrossRefGoogle Scholar
  31. 31.
    Filippucci E, Farina A, Carotti M, et al. Grey scale and power Doppler sonographic changes induced by intra-articular steroid injection treatment. Ann Rheum Dis. 2004;63(6):740–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Scire CA, Montecucco C, Codullo V, et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford). 2009;48(9):1092–7.CrossRefGoogle Scholar
  33. 33.
    Teh J, Stevens K, Williamson L, et al. Power Doppler ultrasound of rheumatoid synovitis: quantification of therapeutic response. Br J Radiol. 2003;76(912):875–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Estimation of inflammation by Doppler ultrasound: quantitative changes after intra-articular treatment in rheumatoid arthritis. Ann Rheum Dis. 2003;62(11):1049–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther. 2012;14(3):R112.PubMedCrossRefGoogle Scholar
  36. 36.
    Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Saleem B, Brown AK, Keen H, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum. 2009;60(7):1915–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86.PubMedCrossRefGoogle Scholar
  39. 39.
    Bijlsma JW, Hoes JN, Van Everdingen AA, et al. Are glucocorticoids DMARDs? Ann N Y Acad Sci. 2006;1069:268–74.PubMedCrossRefGoogle Scholar
  40. 40.
    van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, et al. The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies. Arthritis Rheum. 2004;51(2):233–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Govoni M, Caporali R. Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand? Clin Exp Rheumatol. 2012;30(4):459–63.PubMedGoogle Scholar
  42. 42.
    Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis. 2012. [Epub ahead of print]Google Scholar
  43. 43.
    Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;(1):CD006356.Google Scholar
  44. 44.
    Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007;56(2):399–408.PubMedCrossRefGoogle Scholar
  45. 45.
    Straub RH, Cutolo M, Buttgereit F, et al. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010;267(6):543–60.PubMedCrossRefGoogle Scholar
  46. 46.
    Kirwan JR, Clarke L, Hunt LP, et al. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann N Y Acad Sci. 2010;1193:127–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Vogt M, Derendorf H, Kramer J, et al. Biowaiver monographs for immediate release solid oral dosage forms: prednisone. J Pharm Sci. 2007;96(6):1480–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Kirkham BW, Panayi GS. Diurnal periodicity of cortisol secretion, immune reactivity and disease activity in rheumatoid arthritis: implications for steroid treatment. Br J Rheumatol. 1989;28(2):154–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997;56(1):27–31.PubMedCrossRefGoogle Scholar
  50. 50.
    Cutolo M, Montecucco CM, Cavagna L, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1438–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Cutolo M, Seriolo B, Craviotto C, et al. Circadian rhythms in RA. Ann Rheum Dis. 2003;62(7):593–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Derendorf H, Ruebsamen K, Clarke L, et al. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol. 2012. [Epub ahead of print]Google Scholar
  53. 53.
    Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205–14.PubMedCrossRefGoogle Scholar
  54. 54.
    Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1275–80.PubMedCrossRefGoogle Scholar
  55. 55.
    Alten R, Doring G, Cutolo M, et al. Hypothalamus–pituitary–adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010;37(10):2025–31.PubMedCrossRefGoogle Scholar
  56. 56.
    Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013;72:204–10.Google Scholar
  57. 57.
    Clarke LL, Jessop DS, Hunt LP, et al. Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol. 2011;6(2):241–9.CrossRefGoogle Scholar
  58. 58.
    Jacobs JW, Geenen R, Evers AW, et al. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann Rheum Dis. 2001;60(1):61–4.PubMedCrossRefGoogle Scholar
  59. 59.
    van der Veen MJ, Bijlsma JW. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol. 1993;12(4):500–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Bijlsma JW, Schenk Y, Ramselaar AC, et al. Methylprednisolone pulse therapy in conjunction with azathioprine in rheumatoid arthritis. Clin Rheumatol. 1986;5(4):499–504.PubMedGoogle Scholar
  61. 61.
    Forster PJ, Grindulis KA, Neumann V, et al. High-dose intravenous methylprednisolone in rheumatoid arthritis. Ann Rheum Dis. 1982;41(5):444–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Hansen TM, Dickmeiss E, Jans H, et al. Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis. Ann Rheum Dis. 1987;46(4):290–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Liebling MR, Leib E, McLaughlin K, et al. Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial. Ann Intern Med. 1981;94(1):21–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Neumann V, Hopkins R, Dixon J, et al. Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. Ann Rheum Dis. 1985;44(11):747–51.PubMedCrossRefGoogle Scholar
  65. 65.
    Radia M, Furst DE. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol. 1988;15(2):242–6.PubMedGoogle Scholar
  66. 66.
    Smith MD, Ahern MJ, Roberts-Thomson PJ. Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? Ann Rheum Dis. 1988;47(1):28–33.PubMedCrossRefGoogle Scholar
  67. 67.
    Smith MD, Bertouch JV, Smith AM, et al. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I: clinical effects. J Rheumatol. 1988;15(2):229–32.PubMedGoogle Scholar
  68. 68.
    Williams IA, Baylis EM, Shipley ME. A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. Lancet. 1982;2(8292):237–40.PubMedCrossRefGoogle Scholar
  69. 69.
    Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis. 2005;64(9):1288–93.PubMedCrossRefGoogle Scholar
  70. 70.
    Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008;67(6):815–22.PubMedCrossRefGoogle Scholar
  72. 72.
    Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol. 2005;32(9):1691–8.PubMedGoogle Scholar
  73. 73.
    Konai MS, Vilar Furtado RN, Dos Santos MF, et al. Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. Clin Exp Rheumatol. 2009;27(2):214–21.PubMedGoogle Scholar
  74. 74.
    Caporali R, Conti F, Alivernini S, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol. 2011;29(3 Suppl 66):S7–14.Google Scholar
  75. 75.
    Pincus T, Swearingen CJ, Luta G, et al. Efficacy of prednisone 1–4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis. 2009;68(11):1715–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Tengstrand B, Larsson E, Klareskog L, et al. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol. 2007;36(5):351–8.PubMedCrossRefGoogle Scholar
  77. 77.
    de Lauretis A, Veeraraghavan S, Renzoni E. Review series. Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease. How does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53–82.PubMedGoogle Scholar
  78. 78.
    Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16(3):206–11.PubMedCrossRefGoogle Scholar
  79. 79.
    Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76(3):377–84.PubMedCrossRefGoogle Scholar
  80. 80.
    van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–93.PubMedCrossRefGoogle Scholar
  82. 82.
    Caporali R, Caprioli M, Bobbio-Pallavicini F, et al. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139–43.PubMedCrossRefGoogle Scholar
  83. 83.
    Cimmino MA, Moggiana G, Montecucco C, et al. Long term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis. 1994;53(5):331–3.PubMedCrossRefGoogle Scholar
  84. 84.
    Montecucco C, Caporali R, Caprotti P, et al. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol. 1992;19(12):1895–900.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Roberto Caporali
    • 2
  • Monica Todoerti
    • 1
  • Garifallia Sakellariou
    • 1
  • Carlomaurizio Montecucco
    • 1
  1. 1.Division of RheumatologyUniversity of Pavia, IRCCS S. Matteo FoundationPaviaItaly
  2. 2.Divisione di ReumatologiaPoliclinico San MatteoPaviaItaly

Personalised recommendations